Objective To investigate the efficacy of venetoclax combined with hypomethylating agents(Ven-HMA),in patients with core binding factor acute myeloid leukemia(CBF-AML)intolerant to intensive induction therapy.Methods T...Objective To investigate the efficacy of venetoclax combined with hypomethylating agents(Ven-HMA),in patients with core binding factor acute myeloid leukemia(CBF-AML)intolerant to intensive induction therapy.Methods This study retrospectively analyzed patients newly diagnosed with CBF-AML who were aged<60 years and who received Ven-HMA as induction therapy at the Department of Hematology,the First Affiliated Hospital of Soochow University,between January 2020 and June 2023.展开更多
文摘Objective To investigate the efficacy of venetoclax combined with hypomethylating agents(Ven-HMA),in patients with core binding factor acute myeloid leukemia(CBF-AML)intolerant to intensive induction therapy.Methods This study retrospectively analyzed patients newly diagnosed with CBF-AML who were aged<60 years and who received Ven-HMA as induction therapy at the Department of Hematology,the First Affiliated Hospital of Soochow University,between January 2020 and June 2023.
